Welcome to The Weekly Skin Scan where our editors keep you up-to-date on the latest news and research that could impact your practice. Browse more stories here.
Betsy Wernli, M.D., board-certified dermatologist and president of Forefront Dermatology, shares the unique ways that her practice has adapted care during the pandemic.
Read insights from Bobby Buka, M.D., J.D., CEO and co-founder of The Dermatology Specialist, as he continues to practice dermatology at the epicenter of the COVID-19 pandemic in New York.
Jules Lipoff, M.D., dermatologist and assistant professor of clinical dermatology, Penn Medicine, discusses the importance of telemedicine in the era of COVID-19.
A recent clinical review proves trifarotene 0.005% cream is an effective and safe treatment for acne vulgaris on the face and neck in patients 9 years and older. Currently, the drug is one of four topical retinoid acne treatments available on the market.
Mast cells appear to play an intricate role in the pathophysiology of rosacea and could serve as potential targets for future therapies, according to recent study findings.
The interleukin-23 antagonist guselkumab demonstrated greater efficacy compared with adalimumab and secukinumab at week 48 in controlled clinical trials investigating treatment of moderate-to-severe plaque psoriasis.
A recent meta-analysis confirms cyclosporine as the most effective atopic dermatitis (AD) treatment at the molecular level, although dupilumab achieves broad cutaneous changes beyond those expected with specific Th2 inhibition.
